The omicron-targeted vaccines made by Moderna and Pfizer will become available to children ages 6 months and older after the CDC signs off.
U.S. regulators on Thursday cleared doses of the updated Covid-19 vaccines for children younger than age 5.
The FDA now has cleared their use in tots starting at age 6 months — but just who is eligible depends on what vaccinations they’ve already had, and which kind. Few youngsters have gotten the full primary series, since shots for the littlest kidsChildren under age 6 who’ve already gotten two original doses of Moderna’s Covid-19 vaccine can get a single booster of Moderna’s updated formula if it’s been at least two months since their last shot.
Children under 5 who already got all three Pfizer doses aren’t yet eligible for an updated booster. Data expected next month should help the FDA determine if and when those tots need the omicron-targeted booster. Just 3% of tots under 2 and nearly 5% of those 2 to 4 have gotten their primary doses so far, according to the CDC.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New Research: Your Choice of COVID Vaccine Can Increase Your Risk of MyocarditisThe study found that Moderna had greater rates of heart inflammation than Pfizer, although the overall risk remained extremely low. In comparison to the Pfizer BioNTech COVID-19 vaccine, the Moderna Spikevax COVID-19 vaccine has a two- to three-fold greater incidence of myocarditis, pericarditis, o
Read more »
GSK, Pfizer, Sanofi fend off thousands of U.S. lawsuits over alleged Zantac cancer linkDrugmakers GSK Plc , Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday were spared thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.
Read more »
Pfizer partners with Clear Creek Bio to develop oral COVID-19 drugPfizer Inc and Clear Creek Bio Inc on Tuesday announced a collaboration to identify a potential drug candidate and develop a new class of oral treatment against COVID-19, as Pfizer seeks to expand its anti-infective pipeline.
Read more »
GSK, Pfizer, Sanofi escape U.S. federal litigation over ZantacDrugmakers GSK Plc , Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday defeated thousands of lawsuits in U.S. federal court claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.
Read more »
FDA Expected to Decide on Pfizer RSV Vaccine for Older Adults by May 2023Pfizer said the FDA has accepted its RSV vaccine candidate for review under an expedited process that reduces the approval process by four months.
Read more »
Pfizer Says FDA Will Fast Track Review of RSV VaccinePfizer said the Food and Drug Administration has agreed to a priority review of its candidate vaccine for respiratory syncytial virus for people 60 and older.
Read more »